According to a study, patients with thyroid eye disease treated with the minimally invasive insulin-like growth factor I blocking antibody teprotumumab saw improvements in their symptoms, appearance, and quality of life.
Patients with thyroid eye disease who used the minimally invasive insulin-like growth factor I blocking antibody, teprotumumab, experienced improvement in their symptoms, appearance and quality of life, according to a study recently published in the New England Journal of Medicine.
Nearly three years into the pandemic, many of us now carry antibodies against the virus--due to an infection or two, a few doses of mRNA vaccine, or a round of monoclonal-antibody treatment. But not all immune responses are created equal, and how we first developed our antibodies may influen
The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab--a novel, patient-tailored monoclonal antibody therapy--showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers report
A variety of intricate cancer therapies known as antibody-drug conjugates (ADCs) have undergone clinical testing and been approved for use on patients. To explain the possible risks associated with these medications, researchers have conducted an extensive analysis of different scientific da
ADCs, or antibody drug conjugates, are a class of complicated cancer treatments that have undergone extensive testing in clinical studies. The study explained the potential hazards related to these drugs.
Type I interferon (IFN) is a strong immune activator found in high concentrations in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab, a human mon
While vaccines are one of the most powerful public health tools for protecting against infectious disease, not everybody is conferred the same level of protection. Many factors determine whether an individual responding to vaccination will generate an effective response, including specific b
The study discovered new treatments that can assist patients with multiple myeloma, a blood cancer, who have tried the immunotherapy CAR-T but have experienced relapses.